Transarterial chemoembolization plus lenvatinib with or without protein-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus

Figure 3 Comparison of objective response rate and disease control rate. A: Comparison of objective response rate (ORR) and disease control rate (DCR) between transarterial arterial chemoembolization combined with lenvatinib plus death protein-1 inhibitors (TACE-L-P) and transarterial chemoembolization combined with lenvatinib groups based on Modified Response Evaluation Criteria In Solid Tumors criteria after propensity score matching; B: Comparison of ORR and DCR within the TACE-L-P group stratified by programmed death ligand-1 inhibitors (Sintilimab vs Camrelizumab/Tislelizumab). CR: Complete response; DCR: Disease control rate; HCC-PVTT: Hepatocellular carcinoma with portal vein tumor thrombus; ORR: Objective response rate; PD: Death protein; PD-L1: Programmed death ligand-1; PR: Partial response; SD: Stable disease; TACE-L: Transarterial chemoembolization combined with lenvatinib; TACE-L-P: Transarterial arterial chemoembolization combined with lenvatinib plus death protein-1 inhibitors.